Bispecific antibody News and Research

RSS

Study reveals how cancer cells escape death by lymphocytes

Immunotherapy continues to show exciting promise in more effectively combating several tumor types. Many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.

24 Feb 2021

Nanobodies protect against SARS-CoV-2 variants in animal model

Nanobodies are a potential therapeutic strategy for treating COVID-19. While many previous studies report nanobodies active against SARS-CoV-2 in vitro, none have been evaluated via animal models' intranasal administration.

15 Feb 2021

Bispecific antibody shows efficacy against new SARS-CoV-2 variants

A team of international scientists has recently developed a bispecific antibody that can bind two non-overlapping regions of the spike receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and completely prevent the viral-host interaction.

25 Jan 2021

Second-generation double antibody protects from SARS-CoV-2 and its tested variants

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants. It also prevents the virus from mutating to resist the therapy.

24 Jan 2021

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

7 Jan 2021

Challenges in High Complexity Flow Cytometry

In this interview, Dra. Mª José Marco from the Department of Hematology at Hopsital Dr. Peset talks to News-Medical Life Sciences about high complexity flow cytometry and the challenges they often face.

From Beckman Coulter Life Sciences - Flow Cytometry 24 Sep 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.

3 Feb 2020

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Turbine, a simulation-first drug discovery company, today announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.

21 Jan 2020

IONTAS antibody for the treatment of B-Cell ALL receives approval for clinical trials

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has been informed that International Biotechnology Center Generium, a leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia.

From IONTAS 11 Dec 2019

Chemotherapy can cause drug-resistant mutations in pediatric ALL patients who relapse

Chemotherapy has helped make the most common childhood cancer one of the most curable, but researchers have evidence that the treatment may also prime some patients for relapse.

2 Nov 2019

AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma

AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

12 Feb 2019

Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics

Integral Molecular, the industry leader in the discovery of monoclonal antibodies against membrane proteins, and Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.

12 Dec 2018

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

Scientists equip new virus that kills carcinoma cells with protein

Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

19 Nov 2018

VTT, Dyadic to present data highlighting achievements in development of fungal production platform

VTT and Dyadic International, Inc., today announced that VTT scientists will present the excellent results in their collaboration over the past two years at two international conferences: AAPS PharmSci on November 7th in Washington DC and PEGS Europe on November 14th in Lisbon.

5 Nov 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

New nuclear medicine approach shows potential for precision treatment of solid tumors

A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer--including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children.

26 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Scientists engineer bi-specific antibodies that attract immune killers directly to cancer cells

Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.

30 May 2018